Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome Orrin Devinsky, Anup D. Patel, Elizabeth A. Thiele, Matthew H. Wong, Richard Appleton, Cynthia L. Harden, Sam Greenwood, Gilmour Morrison, and Kenneth Sommerville, On behalf of the GWPCARE1 Part A Study Group Neurology® 2018, 0:e1-e8. doi:10.1212/WNL.0000000000005254 Abstract Objective : To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol (CBD) in children with Dravet syndrome. Methods : Patients aged 4–10 years were randomized 4:1 to CBD (5, 10, or 20 mg/kg/d) or placebo taken twice daily. The double-blind trial comprised 4-week baseline, 3-week treatment (including titration), 10-day taper, and 4-week follow-up periods. Completers [...]
Lire la suiteA Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects. G. Morrison, J. Crockett, G. Blakey, K. Sommerville Clinical Pharmacology in Drug Development, 2019, PMID : 30791225, DOI : 10.1002/cpdd.665 Abstract GW Pharmaceuticals' formulation of highly purified cannabidiol oral solution is approved in the United States for seizures associated with Lennox-Gastaut and Dravet syndromes in patients aged ≥2 years, for which clobazam, stiripentol, and valproate are commonly used antiepileptic drugs. This open-label, fixed-sequence, drug-drug interaction, healthy volunteer trial investigated the impact of cannabidiol on steady-state pharmacokinetics of clobazam (and N-desmethylclobazam), stiripentol, and valproate; [...]
Lire la suiteVariétés de Cannabis: Par Docteur Ethan Russo http://www.cannabis-med.org/index.php?tpl=faq&red=faqlist&id=172&lng=fr Les consommateurs de cannabis ont souvent indiqué que les différentes variétés de cannabis produisent des effets variables, que se soit concernant les effets psychoactifs ou les bénéfices thérapeutiques. Les variétés sont généralement désignées comme étant soit Sativa, soit Indica, soit hybrides. Or, ces noms, d’un point de vue commercial, prêtent à confusion. Pour cette raison, la communauté scientifique s’est concentrée sur le Tétrahydrocannabinol (THC) qu’elle considérait comme la principale variable et la seule d’importance. En parallèle, jusqu’à très récemment, les croisements sélectifs des variétés de cannabis, destiné à l’usage récréatif ou à l’usage thérapeutique, [...]
Lire la suiteIACM-Bulletin du 11 Mars 2019 http://www.cannabis-med.org/french/bulletin/ww_fr_db_cannabis_artikel.php?id=481 Science/Homme: Les lois américaines sur le cannabis médical permettent aux jeunes de consommer moins de cannabis Science/Homme: Les effets médicinaux du cannabis sont principalement basés sur le THC et les fleurs de cannabis ont été les plus efficaces Mexique: La Cour Suprême juge que l’interdiction complète de la consommation de cannabis est inconstitutionnelle Science: Des levures génétiquement modifiées peuvent produire du THC, du CBD et d'autres cannabinoïdes Science/Homme: Une combinaison de CBD et de PEA peut réduire la perméabilité de la paroi de l'intestin pendant l'inflammation En bref [...]
Lire la suitePsilocybin with psychological support for treatment resistant depression : six-month follow-up R. L. Carhart-Harris, M. Bolstridge, C. M. J. Day, J. Rucker, R. Watts, D. E. Erritzoe, M. Kaelen, B. Giribaldi, M. Bloomfield, S. Pilling, J. A. Rickard, B. Forbes, A. Feilding, D. Taylor, H. V. Curran, D. J. Nutt Psychopharmacology, 2017 https://doi.org/10.1007/s00213-017-4771-x Abstract : Rationale : Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. Objectives : Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. Methods : Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant [...]
Lire la suitePsychedelics and hypnosis : Commonalities and therapeutic implications Clément E. Lemercier, Devin B. Terhune Journal of Psychopharmacology, 2018, 32, 7, 732-740. DOI : 10.1177/0269881118780714 Abstract Background : Recent research on psychedelics and hypnosis demonstrates the value of both methods in the treatment of a range of psychopathologies with overlapping applications and neurophenomenological features. The potential of harnessing the power of suggestion to influence the phenomenological response to psychedelics toward more therapeutic action has remained unexplored in recent research and thereby warrants empirical attention. Aims : Here we aim to elucidate the phenomenological and neurophysiological similarities and dissimilarities between psychedelic states and hypnosis in order to revisit [...]
Lire la suiteL’amende forfaitaire pour usage de drogues doit être censurée par le Conseil constitutionnel Dix-neuf organisations demandent aux Sages de censurer l’article 58 de la loi de programmation 2018-2022 de réforme pour la justice qui est contraire à la Constitution. Cet article prévoit que le délit d’usage de stupéfiants peut désormais faire l’objet d’une amende forfaitaire de 200€. Monsieur le Président du Conseil constitutionnel, Mesdames et Messieurs les Membres du Conseil constitutionnel 2, rue Montpensier 75001 Paris. Paris, le 28 février 2019 Objet : Affaire n° 2019-778 DC Monsieur le Président du Conseil constitutionnel, Mesdames et Messieurs les membres du Conseil constitutionnel, Nous, organisations non-gouvernementales françaises, vous adressons ce jour notre [...]
Lire la suiteCannabinoid-Based Therapies and Brain Development : Potential Harmful Effect of Early Modulation of the Endocannabinoid System. Patricia Schonhofen, Ivi Juliana Bristot, José Alexandre Crippa, Jaime Eduardo Cecilio Hallak, Antonio Waldo Zuardi, Richard B. Parsons, Fabio Klamt CNS Drugs, 2018, 32 (Suppl 1), 1-16 https///doi.org/10.1007/s40263-018-0550-4 Abstract : The endocannabinoid retrograde signaling pathway is widely expressed in the central nervous system, where it plays major roles in regulating synaptic plasticity (excitatory and inhibitory) through long-term potentiation and long-term depression. The endocannabinoid system (ECS) components-cannabinoid receptors, endocannabinoids and synthesis/degradation enzymes-are expressed and are functional from early developmental stages and throughout adolescent cortical development, regulating progenitor cell fate, neural [...]
Lire la suiteCannabidiol attenuates deficits of visuospatial associative memory induced by D9tetrahydrocannabinol M. Jerry Wright Jr, Sophia A. Vandewater and Michael A. Taffe Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA, USA British Journal of Pharmacology, 2013, 170, 1365–1373 BACKGROUND AND PURPOSE Recent human studies suggest that recreational cannabis strains that are relatively high in cannabidiol (CBD) content produce less cognitive impairment than do strains with negligible CBD and similar D9tetrahydrocannabinol (THC) content. Self-selection in such studies means it is impossible to rule out additional variables which may determine both cannabis strain selection and basal cognitive performance level. Controlled laboratory studies can [...]
Lire la suiteNeurobiology of Disease : Daily Marijuana Use Is Not Associated with Brain Morphometric Measures in Adolescents or Adults Barbara J. Weiland, Rachel E. Thayer, Brendan E. Depue, Amithrupa Sabbineni, Angela D. Bryan, and Kent E. Hutchison Department of Psychology and Neuroscience, University of Colorado Boulder, Boulder, Colorado 80309, Department of Psychological and Brain Sciences, University of Louisville, Louisville, Kentucky 40292 The Journal of Neuroscience, 2015, 35, 4, 1505–1512. DOI : 10.1523/JNEUROSCI.2946-14.2015 Abstract : Recent research has suggested that marijuana use is associated with volumetric and shape differences in subcortical structures, including the nucleus accumbens and amygdala, in a dose-dependent fashion. Replication of such results in well controlled [...]
Lire la suite